AF in Cancer Patients: A Different Need for Anticoagulation?
Cancer and cancer therapies might be a risk factor for developing Atrial Fibrillation (AF). It remains unclear if one is the cause or consequence of the other, or if they simply coexist. An unpredictable response to anticoagulation can be expected, as a result of the lack of information in oncology...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Radcliffe Medical Media
2019-01-01
|
| Series: | European Cardiology Review |
| Online Access: | https://www.ecrjournal.com/articles/af-cancer-patients-different-need-anticoagulation |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850110980292345856 |
|---|---|
| author | Ana Pardo Sanz José Luis Zamorano Gómez |
| author_facet | Ana Pardo Sanz José Luis Zamorano Gómez |
| author_sort | Ana Pardo Sanz |
| collection | DOAJ |
| description | Cancer and cancer therapies might be a risk factor for developing Atrial Fibrillation (AF). It remains unclear if one is the cause or consequence of the other, or if they simply coexist. An unpredictable response to anticoagulation can be expected, as a result of the lack of information in oncology patients. The balance between thromboembolic and bleeding risks of AF in these patients is particularly challenging. Little is known about whether embolic and bleeding risk scores used for the general population can be applied in oncologic patients. Cardiology involvement in the management of these patients seems to be associated with favourable AF-related outcomes. |
| format | Article |
| id | doaj-art-d917cf8638154e9aabb6116bbb7aaa9d |
| institution | OA Journals |
| issn | 1758-3756 1758-3764 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Radcliffe Medical Media |
| record_format | Article |
| series | European Cardiology Review |
| spelling | doaj-art-d917cf8638154e9aabb6116bbb7aaa9d2025-08-20T02:37:42ZengRadcliffe Medical MediaEuropean Cardiology Review1758-37561758-37642019-01-01141656710.15420/ecr.2018.32.2AF in Cancer Patients: A Different Need for Anticoagulation?Ana Pardo Sanz0José Luis Zamorano Gómez1Cardiology Department, Ramón y Cajal Hospital, Madrid, SpainCardiology Department, Ramón y Cajal Hospital, Madrid, Spain; Cardiology Department, University of Alcalá, University Hospital La Zarzuela, SpainCancer and cancer therapies might be a risk factor for developing Atrial Fibrillation (AF). It remains unclear if one is the cause or consequence of the other, or if they simply coexist. An unpredictable response to anticoagulation can be expected, as a result of the lack of information in oncology patients. The balance between thromboembolic and bleeding risks of AF in these patients is particularly challenging. Little is known about whether embolic and bleeding risk scores used for the general population can be applied in oncologic patients. Cardiology involvement in the management of these patients seems to be associated with favourable AF-related outcomes.https://www.ecrjournal.com/articles/af-cancer-patients-different-need-anticoagulation |
| spellingShingle | Ana Pardo Sanz José Luis Zamorano Gómez AF in Cancer Patients: A Different Need for Anticoagulation? European Cardiology Review |
| title | AF in Cancer Patients: A Different Need for Anticoagulation? |
| title_full | AF in Cancer Patients: A Different Need for Anticoagulation? |
| title_fullStr | AF in Cancer Patients: A Different Need for Anticoagulation? |
| title_full_unstemmed | AF in Cancer Patients: A Different Need for Anticoagulation? |
| title_short | AF in Cancer Patients: A Different Need for Anticoagulation? |
| title_sort | af in cancer patients a different need for anticoagulation |
| url | https://www.ecrjournal.com/articles/af-cancer-patients-different-need-anticoagulation |
| work_keys_str_mv | AT anapardosanz afincancerpatientsadifferentneedforanticoagulation AT joseluiszamoranogomez afincancerpatientsadifferentneedforanticoagulation |